Core Points - Verizon has launched preorders for the new Google Pixel 10 series, which includes Pixel 10, Pixel 10 Pro, Pixel 10 Pro XL, and Pixel 10 Pro Fold, on its 5G network [2] - The company offers a three-year price lock guarantee on its myPlan and myHome network plans, ensuring no price hikes for customers [3][7] - The Pixel 10 series features advanced AI capabilities, enhanced camera technology, and improved durability, aiming to redefine the smartphone experience [5][6] Pricing and Offers - Pixel 10 Pro XL starts at $33.33 per month for 36 months ($1,199.99 retail), Pixel 10 Pro at $27.77 per month ($999.99 retail), Pixel 10 at $22.22 per month ($799.99 retail), and Pixel 10 Pro Fold at $49.99 per month ($1,799.99 retail) [8] - Customers can receive significant discounts, such as $1,000 off a Pixel 10 Pro Fold with a trade-in of qualified devices [9] - The Pixel Watch 4 is available starting at $12.49 per month for 36 months ($449.99 retail) [8] Customer Experience and Benefits - Verizon enhances customer experience with exclusive mobile and home discounts, rewards, and events accessible via the My Verizon app [4] - The company provides seamless service and a variety of plans tailored to customer needs, including a special offer for business customers [11][12] - Customers purchasing a Pixel 10 series smartphone can enjoy six months of Google AI Pro for free [10]

Unique nootropic formula blends botanical extracts, amino acids and neuro-support nutrients to support balance, energy and resilience in athletesLAS VEGAS, Aug. 20, 2025 (GLOBE NEWSWIRE) -- via IBN – BioAdaptives, Inc. (OTCMKTS: BDPT), a leader in natural health and performance supplements, today announced that its flagship nootropic formula, MyndMed™, has been officially certified clean by TruShield™ Laboratory Services, a trusted provider of sports supplement testing specializing in World Anti-Doping Agen ...

Regulatory filing of own share purchase on August 14th (document in French only). Attachment Déclaration rachat d'actions propres du 18 août 2025 ...

23, Place des Carmes-Déchaux - 63000 CLERMONT-FERRAND Information about securities repurchasing programRegulated informationIssuer social denomination: Michelin – LEI 549300SOSI58J6VIW052 Types of securities: ordinary shares – Code ISIN FR001400AJ45Date : August 20th, 2025 Issuer NameIssuer codeTransactiondateISIN CodeDaily total volume (in number of actions)Daily weighted average price of shares acquiredPlatformCompagnie Générale des Etablissements Michelin549300SOSI58J6VIW052<td style="width:79.2px;;text- ...

Novonesis today announces its ‘GROW’ strategy and long-term targets for the strategy period until 2030 focusing on an acceleration of the core business and significant re-investments to secure long-term growth. By 2030, the company expects to deliver an organic sales CAGR of 6-9%, an adjusted EBITDA margin of ~39% and an adjusted ROIC excl. goodwill of ~16%. Novonesis is well positioned to continue to drive strong performance in biosolutions. The company is present across multiple end-markets with strong ca ...

Group 1 - Devon Energy Corp. will have its President and CEO, Clay Gaspar, participate in a fireside chat at the Barclays 39th Annual CEO Energy & Power Conference [1] - The event is scheduled for September 3, 2025, at 8:45 a.m. Central time and will be webcast live on Devon's website [1] - A replay of the webcast will be available for 30 days following the event [1] Group 2 - Devon Energy is a leading oil and gas producer in the U.S. with a diversified multi-basin portfolio, particularly noted for its position in the Delaware Basin [2] - The company employs a disciplined cash-return business model aimed at achieving strong returns, generating free cash flow, and returning capital to shareholders [2] - Devon Energy emphasizes safe and sustainable operations in its business practices [2]

Core Viewpoint - Vaisala Corporation has executed a share repurchase, acquiring 900 shares at an average price of 46.9556 EUR per share, totaling a cost of 42,260.04 EUR, which increases its total holdings to 141,384 shares [1]. Group 1: Share Repurchase Details - The share repurchase occurred on August 20, 2025, in compliance with European regulations [1]. - The average price per share during the buyback was 46.9556 EUR [1]. - The total cost of the repurchase was 42,260.04 EUR [1]. Group 2: Company Overview - Vaisala Corporation is a global leader in measurement instruments and intelligence for climate action, focusing on improving resource efficiency and energy transition [2]. - The company has nearly 90 years of innovation and employs around 2,500 experts dedicated to environmental measures [2]. - Vaisala's series A shares are listed on the Nasdaq Helsinki stock exchange [2].

Core Viewpoint - The U.S. FDA has extended the target action dates for Regeneron Pharmaceuticals' EYLEA HD regulatory submissions to the fourth quarter of 2025 due to major amendments resulting from a recent inspection of a third-party manufacturer [1][2] Group 1: Regulatory Updates - The FDA's extension of review periods was prompted by significant information provided after an inspection at Catalent Indiana LLC, which is now owned by Novo Nordisk A/S [2] - Novo Nordisk submitted a comprehensive response to the FDA in early August 2025 to address the observations noted during the inspection [2] - EYLEA HD remains available in the U.S. through vial administration, with approved dosing intervals ranging from every 8 to 16 weeks for various conditions [3] Group 2: Product Information - EYLEA HD is a vascular endothelial growth factor inhibitor developed to provide comparable efficacy and safety to EYLEA but with fewer injections [5] - EYLEA HD is approved in the U.S. for treating patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME), and diabetic retinopathy (DR) [8] - EYLEA HD is being jointly developed by Regeneron and Bayer AG, with Regeneron holding exclusive rights in the U.S. and Bayer having exclusive marketing rights outside the U.S. [6] Group 3: Company Overview - Regeneron is a leading biotechnology company focused on developing life-transforming medicines for serious diseases, leveraging its unique ability to translate science into medicine [11] - The company has a robust research and development program in ophthalmology, aiming to address additional serious eye diseases [7] - Regeneron utilizes proprietary technologies to accelerate drug development and is committed to innovative solutions for patients [12]

Core Viewpoint - goeasy Ltd. successfully closed an upsized offering of senior unsecured notes, reflecting strong market demand and confidence in its business [1][3] Group 1: Offering Details - The company closed an offering of US$450 million in senior unsecured notes due 2031, increased from an initial US$400 million [1] - Additionally, goeasy issued C$175 million in 6.000% senior unsecured notes due 2030, up from C$100 million at the initial offering [1] - The New CAD Notes were issued at a price of C$997.50 per C$1,000 principal amount, plus accrued interest from May 15, 2025 [1] Group 2: Financial Strategy - goeasy entered into a currency swap agreement to reduce the Canadian dollar equivalent cost of borrowing on the USD Notes to 6.106% per annum, down from a coupon of 6.875% [2] - The net proceeds from the sale of the notes will be used to partially repay indebtedness under secured facilities and for general corporate purposes [2] Group 3: Company Overview - goeasy Ltd. is a leading consumer lender in Canada, providing financial services to individuals with near to non-prime credit scores [1] - The company operates through its easyhome, easyfinancial, and LendCare brands, offering a variety of financial products including unsecured and secured installment loans [3] - goeasy has a total funding capacity of C$2.3 billion to support its growth plans [3] Group 4: Awards and Recognition - goeasy has received several awards for its corporate culture and growth, including recognition from TIME Magazine and Waterstone Canada [4] - The company has raised and donated over C$6.5 million to support local charities and partnerships [4]

Austin, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- DBGI Corp. (Ticker: [NASDAQ:DBGI] a publicly traded company specializing in eCommerce and Fashion today announced it will commence trading on The Nasdaq Capital Market ("Nasdaq") under its current ticker symbol “DBGI” on Wednesday, August 20, 2025. The uplisting to Nasdaq marks a key milestone in the Company’s evolution, designed to enhance investor visibility, increase liquidity, and allow Digital Brands Group to pursue its growth strategy. The Company belie ...